Condition Guide

Peptides for Weight Loss

Peptide therapy is the most rapidly evolving area of weight-loss medicine. GLP-1 receptor agonists like semaglutide and dual GIP/GLP-1 agonists like tirzepatide deliver 15-25% body weight reduction in Phase III trials — effects previously achievable only with bariatric surgery.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

How peptides help

Weight-loss peptides work primarily by activating incretin receptors (GLP-1, GIP) in the pancreas, gut, and hypothalamus. The result is reduced appetite, slower gastric emptying, improved insulin sensitivity, and central satiety. Newer triple agonists add glucagon receptor activation to increase energy expenditure, producing the largest weight-loss effects ever recorded in pharmacology.

Peptides researched for weight loss

Semaglutide

Strong EvidenceL5

FDA approved. 15% mean weight loss at 68 weeks in STEP trials.

630 studies · GLP-1 Receptor Agonism

Tirzepatide

Strong EvidenceL5

FDA approved. 20-22% mean weight loss in SURMOUNT-1; superior to semaglutide head-to-head.

180 studies · Dual GIP/GLP-1 Agonism

Retatrutide

Moderate EvidenceL4

Phase III. Phase II reported ~24% weight loss — largest ever observed.

31 studies · Triple GIP/GLP-1/Glucagon Agonism

AOD-9604

PreliminaryL2

Phase II; selective lipolytic effect without GH side effects.

23 studies · Lipolytic GH Fragment Activity

MOTS-c

PreliminaryL2

Early-stage research; mitochondrial AMPK activation improves metabolic flexibility.

43 studies · Mitochondrial-Derived AMPK Activation

State of the evidence

Multiple FDA-approved options exist (Wegovy, Zepbound), with extensive cardiovascular outcome data from SELECT, STEP, and SURMOUNT trials. Evidence strength here is the highest of any peptide category.

Frequently asked

Which peptide produces the most weight loss?

In published Phase III data, tirzepatide produces the largest FDA-approved weight loss (20-22% at 72 weeks). Retatrutide in Phase II produced ~24% loss but is not yet approved.

How long does weight loss from GLP-1 peptides last?

Weight loss is maintained only while medication continues. Extension trials (STEP-4, SURMOUNT-4) show significant weight regain within a year of stopping, suggesting obesity is a chronic condition requiring ongoing treatment.

Are peptide weight-loss treatments safe long-term?

GLP-1 agonists have 15+ years of real-world safety data from diabetes use. Common side effects are GI-related (nausea, constipation). Rare serious events include pancreatitis and gallbladder disease. Newer agents have less long-term data.

Can I compound semaglutide or tirzepatide?

Following the end of the FDA shortage designation in 2024-2025, compounding of copies of brand-name semaglutide and tirzepatide is restricted. See our FDA Tracker for current status.